Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolent Health, Inc.EVH · Entity 5492 | Director | June 13, 2018 | June 15, 2018 |
| Progyny, Inc.PGNY · Entity 4521 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolent Health, Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 21,284 |
Reported balance
After 2018-06-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 5,459 · Balance 21,284 F1: Represents restricted stock units granted to Dr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to Dr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
F2: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date.
F3: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
Progyny, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,349 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 5,660 · Balance 12,349 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.69 · Expires 2036-05-20 | Direct | 3,203 |
Reported balance
After 2026-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-21 · Grant · Acquired 3,203 · Balance 3,203 F4: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.69 · Expires 2036-05-20 | Direct | 27,119 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Grant · Acquired 27,119 · Balance 27,119 F5: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 331,363 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 331,363 F2: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 122,493 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 122,493 F3: The reportable securities are directly held by EVO Eagle, LLC. The Reporting Person shares voting and dispositive power over the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
F2: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust.
F3: The reportable securities are directly held by EVO Eagle, LLC. The Reporting Person shares voting and dispositive power over the securities.
F4: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
F5: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apria, Inc.
Report date March 29, 2022 · Filed March 29, 2022
Section 16 reporting ended · disclosed 2022-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-29 · Disposition to issuer · Disposed 5,059 · Balance 0 F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee.
F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.
F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2021 Filed Nov 12, 2021 22:38 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,849 | $61.92 | $238,330.08 |
DisclosureSEC source: 0001179110-21-010104 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 618,457 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.53 to $62.42, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) , (7), (8), (9) and (10). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 20:56 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,102 | $61.69 | $129,672.38 |
DisclosureSEC source: 0001179110-21-009907 · edgar.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 622,306 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.58 to $61.88, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 20:56 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,421 | $61.24 | $270,742.04 |
DisclosureSEC source: 0001179110-21-009907 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 624,408 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.58 to $61.57, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 20:56 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,807 | $60.17 | $108,727.19 |
DisclosureSEC source: 0001179110-21-009907 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 628,829 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.58 to $60.56, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:56 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,901 | $62.79 | $119,363.79 |
DisclosureSEC source: 0001179110-21-009907 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 630,636 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.36 to $63.22, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:56 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,191 | $61.68 | $135,140.88 |
DisclosureSEC source: 0001179110-21-009907 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 632,537 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.36 to $62.335, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:56 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,238 | $60.63 | $256,949.94 |
DisclosureSEC source: 0001179110-21-009907 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 634,728 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $61.05, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 20:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,050 | $60.66 | $245,673.00 |
DisclosureSEC source: 0001179110-21-009710 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 638,966 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.19 to $61.11 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 20:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,280 | $59.76 | $255,772.80 |
DisclosureSEC source: 0001179110-21-009710 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 643,016 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.18 to $60.09 inclusive. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 504 | $61.30 | $30,895.20 |
DisclosureSEC source: 0001179110-21-009710 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 647,296 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.0 to $61.4 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:46 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 7,826 | $60.65 | $474,646.90 |
DisclosureSEC source: 0001179110-21-009710 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 647,800 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.99 to $60.98, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 21:52 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (right to buy) · Derivative | 15,244 | $0.00 Strike: $63.21 | $0.00 |
DisclosureSEC source: 0001179110-21-009639 · edgar.xml · derivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,244 Underlying: Common Stock · 15,244 shares Expires 2026-10-23 F4 · derivative.exercise_date: The shares subject to the Option shall vest on October 24, 2022, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 21:52 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 2,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009639 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,652 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on October 24, 2022, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 7,030 | $60.95 | $428,478.50 |
DisclosureSEC source: 0001179110-21-009601 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 655,626 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.465 to $61.420, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,300 | $59.86 | $77,818.00 |
DisclosureSEC source: 0001179110-21-009601 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 662,656 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $60.30, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 200 | $59.61 | $11,922.00 |
DisclosureSEC source: 0001179110-21-009601 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 663,956 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.570 to $59.645, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,730 | $58.85 | $396,060.50 |
DisclosureSEC source: 0001179110-21-009601 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 664,156 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.515 to $59.485, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,400 | $58.07 | $81,298.00 |
DisclosureSEC source: 0001179110-21-009601 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 670,886 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.52 to $58.51, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 20:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,700 | $59.25 | $100,725.00 |
DisclosureSEC source: 0001179110-21-009444 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 672,286 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.990 to $59.905, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 20:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,630 | $58.21 | $385,932.30 |
DisclosureSEC source: 0001179110-21-009444 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 673,986 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.86 to $58.85, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 100 | $58.83 | $5,883.00 |
DisclosureSEC source: 0001179110-21-009444 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 680,616 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:35 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 8,230 | $58.36 | $480,302.80 |
DisclosureSEC source: 0001179110-21-009444 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 680,716 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.78 to $58.64, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,916 | $59.97 | $234,850.35 |
DisclosureSEC source: 0001179110-21-009305 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 688,946 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.40, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,414 | $59.13 | $260,999.82 |
DisclosureSEC source: 0001179110-21-009305 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 692,862 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.45 to $59.43, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,650 | $57.60 | $152,640.00 |
DisclosureSEC source: 0001179110-21-009305 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 697,276 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.48 to $57.73, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,180 | $56.93 | $237,967.40 |
DisclosureSEC source: 0001179110-21-009305 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 699,926 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $57.47, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:40 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,500 | $55.98 | $83,970.00 |
DisclosureSEC source: 0001179110-21-009305 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 704,106 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.47 to $56.46, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7) and (8). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 22:24 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,505 | $57.10 | $143,025.48 |
DisclosureSEC source: 0001179110-21-009052 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 705,606 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.825 to $57.27, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 22:24 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,825 | $56.27 | $327,743.63 |
DisclosureSEC source: 0001179110-21-009052 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 708,111 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.83 to $56.79, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 22:24 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,178 | $55.73 | $232,839.94 |
DisclosureSEC source: 0001179110-21-009052 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 713,936 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.48 to $56.19, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 22:24 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,152 | $55.17 | $229,065.84 |
DisclosureSEC source: 0001179110-21-009052 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 718,114 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.48 to $55.47, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,655 | $63.49 | $105,075.95 |
DisclosureSEC source: 0001179110-21-008920 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 722,266 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.40 to $63.74 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,675 | $63.14 | $421,459.50 |
DisclosureSEC source: 0001179110-21-008920 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 723,921 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.40 to $63.39 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,291 | $62.06 | $204,239.46 |
DisclosureSEC source: 0001179110-21-008920 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 730,596 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.37 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,039 | $61.36 | $309,172.88 |
DisclosureSEC source: 0001179110-21-008920 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 733,887 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.79 to $61.71, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 200 | $61.82 | $12,364.00 |
DisclosureSEC source: 0001179110-21-008841 · edgar.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 738,926 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.785 to $61.85 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 8,130 | $61.25 | $497,962.50 |
DisclosureSEC source: 0001179110-21-008841 · edgar.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 739,126 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.675 to $61.63 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 800 | $60.86 | $48,688.00 |
DisclosureSEC source: 0001179110-21-008841 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 747,256 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.81 to $60.95 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,729 | $60.32 | $285,253.28 |
DisclosureSEC source: 0001179110-21-008841 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 748,056 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.74 to $60.71 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,401 | $59.24 | $142,235.24 |
DisclosureSEC source: 0001179110-21-008841 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 752,785 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.73 to $59.65 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 400 | $58.06 | $23,224.00 |
DisclosureSEC source: 0001179110-21-008841 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 755,186 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.73 to $58.66, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 900 | $58.62 | $52,758.00 |
DisclosureSEC source: 0001179110-21-008713 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 755,586 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.585 to $58.695 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 7,430 | $58.36 | $433,614.80 |
DisclosureSEC source: 0001179110-21-008713 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 756,486 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.59 to $58.58 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,356 | $57.87 | $136,341.72 |
DisclosureSEC source: 0001179110-21-008713 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See foonote Disclosed balance after: 763,916 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.55 to $58.23 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 20:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,974 | $57.18 | $341,593.32 |
DisclosureSEC source: 0001179110-21-008713 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 766,272 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.55 to $57.54, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,372 | $56.50 | $134,018.00 |
DisclosureSEC source: 0001179110-21-008592 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 772,246 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.45 to $56.70 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,958 | $56.11 | $334,303.38 |
DisclosureSEC source: 0001179110-21-008592 · edgar.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 774,618 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.46 to $56.445 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,583 | $56.41 | $202,117.03 |
DisclosureSEC source: 0001179110-21-008592 · edgar.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 780,576 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.25 to $56.58 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:41 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,747 | $55.85 | $265,119.95 |
DisclosureSEC source: 0001179110-21-008592 · edgar.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 784,159 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.25 to $56.24, inclusive. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 22:31 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 41 | $51.85 | $2,125.85 |
DisclosureSEC source: 0001179110-21-008463 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 788,906 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.